Guiyang Xintian Pharmaceutical Co.,Ltd.

002873

CNE100002QB5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
11.91 ^CNY	+2.41%		+6.62%	-4.41%

Apr. 27	Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 12	Guiyang Xintian Pharmaceutical Co.,Ltd. Announces Profit Distribution Proposal for 2023	CI

Tranche Update on Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024.

April 01, 2024 at 12:00 pm EDT

From February 4, 2024 to March 31, 2024, the company has repurchased 8,806,030 shares, representing 3.81% for CNY 75.3 million. With this, the company has completed the repurchase of 8,806,030 shares, representing 3.81% for CNY 75.3 million under the buyback announced on February 6, 2024.

Latest news about Guiyang Xintian Pharmaceutical Co.,Ltd.

Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Announces Profit Distribution Proposal for 2023	Apr. 12	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. signed Transaction Framework Agreement to acquire remaining 85.12% stake in Shanghai Huilun Biotechnology Co., Ltd.	Apr. 06	CI
Tranche Update on Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024.	Apr. 01	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Increase in Equity Buyback.	Feb. 05	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	Feb. 05	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.	Feb. 03	CI
Tranche Update on Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on December 23, 2023.	Feb. 02	CI
Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback announced on December 23, 2023 has closed with 4,017,200 shares, representing 1.73% for CNY 38.41 million.	Feb. 01	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Increase in Equity Buyback.	Jan. 30	CI
Tranche Update on Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on December 23, 2023.	Jan. 03	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 15 million worth of its shares.	Dec. 22	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.	Dec. 21	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 01 June 2023	23-05-24	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Approves Cash Dividend for the Year of 2022	23-04-21	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for the Year of 2022	23-03-27	CI
Guiyang Xintian Pharma Tapped to Produce Traditional Chinese Medicine for Hospital	22-12-27	MT
Shanghai Huilun Biotechnology Co., Ltd. announced that it has received CNY 102 million in funding from Guiyang Xintian Pharmaceutical Co.,Ltd. and other investors	22-12-12	CI
Shanghai Huilun Biotechnology Co., Ltd. announced that it expects to receive CNY 102 million in funding from Guiyang Xintian Pharmaceutical Co.,Ltd. and other investors	22-10-27	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Announces 2021 Final Profit Distribution Plan, Payable on 7 July 2022	22-06-30	CI

Chart Guiyang Xintian Pharmaceutical Co.,Ltd.

Duration

Period

Chart Guiyang Xintian Pharmaceutical Co.,Ltd.

More charts

Company Profile

Guiyang Xintian Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and sales of Chinese patent drugs. The Company manufactures its products in the forms of capsules, mixture, granules, syrup, gel and tablets. The Companyâs main products include Ningmitai Capsule, Kuntai Capsule, Kushen Gel and Xiaokucao Oral Liquid .The Company distributes its products in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Guiyang Xintian Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

11.63

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
GUIYANG XINTIAN PHARMACEUTICAL CO.,LTD.	-4.41%	370M
MERCK KGAA	+3.37%	69.85B
KYOWA KIRIN CO. LTD.	+11.77%	8.98B
SK BIOPHARMACEUTICALS CO., LTD.	-12.75%	4.89B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+42.38%	4.44B
YUHAN CORPORATION	+5.23%	3.95B
INDIVIOR PLC	+21.69%	2.49B
BETTA PHARMACEUTICALS CO., LTD.	-19.05%	2.4B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.72%	2.28B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.13%	1.96B

Specialty & Advanced Pharmaceuticals

Guiyang Xintian Pharmaceutical Co.,Ltd.

Equities

002873

CNE100002QB5

Pharmaceuticals

Tranche Update on Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024.

Latest news about Guiyang Xintian Pharmaceutical Co.,Ltd.

Chart Guiyang Xintian Pharmaceutical Co.,Ltd.

Company Profile

Income Statement Evolution

Ratings for Guiyang Xintian Pharmaceutical Co.,Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals